{
  "created_at": "2025-10-27T11:47:05.363888",
  "total_templates": 4,
  "templates": {
    "retention": {
      "scenario": "retention",
      "target_segment": "At-risk HCPs (high volume + declining IBSA share)",
      "identified_count": 660,
      "goal": "Prevent churn and regain market share",
      "priority": "HIGH",
      "dynamic_slots": [
        "{hcp_name}",
        "{specialty}",
        "{current_trx}",
        "{trx_decline_pct}",
        "{ibsa_share}",
        "{competitive_threat}",
        "{product_focus}"
      ],
      "script_structure": {
        "opening": {
          "greeting": "Good {time_of_day}, Dr. {hcp_name}. Thank you for taking the time to meet with me today.",
          "purpose": "I wanted to discuss {product_focus} and understand how we can better support your practice. I noticed your {product_focus} prescriptions have declined by approximately {trx_decline_pct}% recently, and I'd like to learn more about your current treatment approach.",
          "tone": "Professional, data-driven, consultative"
        },
        "key_talking_points": [
          {
            "point_id": 1,
            "topic": "Acknowledge Change & Seek Understanding",
            "message": "I see that you've been prescribing {competitive_threat} more frequently. Could you share what's driving this change? Understanding your perspective helps me ensure we're addressing your patients' needs.",
            "approved_content_refs": []
          },
          {
            "point_id": 2,
            "topic": "Reinforce Value Proposition",
            "message": "Based on your specialty in {specialty}, {product_focus} may offer specific benefits for certain patient populations. [INSERT PRODUCT-SPECIFIC APPROVED MESSAGING FROM LIBRARY]",
            "approved_content_refs": [
              "TIR-MSG-001",
              "TIR-MSG-002",
              "FLE-MSG-001",
              "LIC-MSG-001"
            ]
          },
          {
            "point_id": 3,
            "topic": "Clinical Evidence",
            "message": "Recent studies have demonstrated [INSERT CLINICAL CLAIMS FROM LIBRARY]. This may be relevant for patients who are not optimally controlled on current therapy.",
            "approved_content_refs": [
              "TIR-CLI-001",
              "TIR-CLI-002",
              "FLE-CLI-001",
              "LIC-CLI-001"
            ]
          },
          {
            "point_id": 4,
            "topic": "Address Competitive Positioning",
            "message": "I understand {competitive_threat} may have certain advantages. However, {product_focus} offers [UNIQUE DIFFERENTIATORS]. For patients with [SPECIFIC NEEDS], this could make a meaningful difference.",
            "approved_content_refs": []
          }
        ],
        "objection_handlers": {
          "price_objection": {
            "objection": "Your product is more expensive than generics/competitors",
            "response": "[USE APPROVED OBJECTION HANDLER: TIR-OBJ-001 or GEN-OBJ-001]",
            "approved_content_refs": [
              "TIR-OBJ-001",
              "GEN-OBJ-001"
            ]
          },
          "efficacy_question": {
            "objection": "I'm not seeing better results with your product",
            "response": "I appreciate that feedback. Could you tell me more about the patient population you're treating? [PRODUCT] may be particularly beneficial for patients with [SPECIFIC CHARACTERISTICS]. Let's discuss whether there might be select patients where [PRODUCT] could be a good fit.",
            "approved_content_refs": [
              "TIR-CLI-001",
              "TIR-CLI-002"
            ]
          },
          "satisfied_with_current": {
            "objection": "I'm satisfied with current therapy options",
            "response": "That's great to hear your patients are doing well. I'm not suggesting changing all patients, but rather keeping [PRODUCT] as an option for those who may not be optimally controlled or have specific needs. Would you be open to considering it for select cases?",
            "approved_content_refs": []
          }
        },
        "call_to_action": {
          "primary_ask": "Would you be willing to try {product_focus} for 3-5 patients who might benefit from [SPECIFIC BENEFIT]?",
          "secondary_ask": "Can I provide you with samples to have available for appropriate patients?",
          "tertiary_ask": "May I schedule a follow-up call in 30 days to discuss your experience?"
        },
        "next_steps": [
          "Leave product samples and dosing information",
          "Send clinical study reprints via email",
          "Schedule follow-up call/visit in 30 days",
          "Provide direct contact for questions",
          "Monitor TRx data for changes"
        ],
        "required_disclaimers": [
          "prescribing_info",
          "individual_results",
          "adverse_events"
        ]
      },
      "success_metrics": {
        "primary": "Halt TRx decline (stop negative trend)",
        "secondary": "Increase sample utilization by 20%",
        "tertiary": "Schedule follow-up meeting within 30 days"
      }
    },
    "growth": {
      "scenario": "growth",
      "target_segment": "Opportunity HCPs (high volume + low IBSA share ~12.9%)",
      "identified_count": 264,
      "goal": "Increase IBSA market share from ~12.9% to 25%+",
      "priority": "HIGH",
      "dynamic_slots": [
        "{hcp_name}",
        "{specialty}",
        "{total_market_trx}",
        "{current_ibsa_share}",
        "{target_ibsa_share}",
        "{product_focus}",
        "{patient_volume}"
      ],
      "script_structure": {
        "opening": {
          "greeting": "Good {time_of_day}, Dr. {hcp_name}. I appreciate you taking the time to see me.",
          "purpose": "I'm here to discuss how {product_focus} might benefit some of your patients. I see you write approximately {total_market_trx} prescriptions in this category, and I'd like to explore whether {product_focus} could be a valuable addition to your treatment options.",
          "tone": "Collaborative, educational, patient-focused"
        },
        "key_talking_points": [
          {
            "point_id": 1,
            "topic": "Product Education",
            "message": "{product_focus} is [INSERT PRODUCT DESCRIPTION FROM LIBRARY]. For your {specialty} practice, this may offer advantages for certain patient populations.",
            "approved_content_refs": [
              "TIR-MSG-001",
              "TIR-MSG-002",
              "FLE-MSG-001",
              "LIC-MSG-001"
            ]
          },
          {
            "point_id": 2,
            "topic": "Clinical Evidence",
            "message": "Clinical studies have shown [INSERT CLINICAL DATA FROM LIBRARY]. This may be particularly relevant for patients who [SPECIFIC PATIENT CHARACTERISTICS].",
            "approved_content_refs": [
              "TIR-CLI-001",
              "TIR-CLI-002",
              "FLE-CLI-001",
              "LIC-CLI-001"
            ]
          },
          {
            "point_id": 3,
            "topic": "Patient Selection Guidance",
            "message": "Based on your patient population, {product_focus} may be especially suitable for patients with: [LIST APPROPRIATE PATIENT CHARACTERISTICS]. Would you have patients fitting this profile?",
            "approved_content_refs": []
          },
          {
            "point_id": 4,
            "topic": "Trial Offer",
            "message": "I'd like to offer samples so you can trial {product_focus} with 3-5 appropriate patients. This allows both you and your patients to evaluate the therapy without financial commitment.",
            "approved_content_refs": [
              "GEN-OBJ-002"
            ]
          }
        ],
        "objection_handlers": {
          "unfamiliar_with_product": {
            "objection": "I'm not familiar with your product",
            "response": "That's completely understandable, and I appreciate your honesty. Let me provide a brief overview: [PRODUCT SUMMARY]. Would you like me to leave educational materials and samples for you to review?",
            "approved_content_refs": [
              "TIR-MSG-001",
              "FLE-MSG-001",
              "LIC-MSG-001"
            ]
          },
          "happy_with_current_portfolio": {
            "objection": "I have enough options already",
            "response": "I understand you have established therapies that work well. I'm not suggesting replacing what's working, but rather adding {product_focus} as another option for patients who may have specific needs or preferences. Could I leave samples for those situations?",
            "approved_content_refs": [
              "GEN-OBJ-001"
            ]
          },
          "need_more_information": {
            "objection": "I need to review more data before trying",
            "response": "Absolutely, that's a prudent approach. Let me provide you with [CLINICAL STUDIES, PRESCRIBING INFORMATION]. Would you be open to a brief follow-up call after you've had a chance to review the materials?",
            "approved_content_refs": [
              "TIR-CLI-001",
              "TIR-CLI-002"
            ]
          }
        },
        "call_to_action": {
          "primary_ask": "Would you be willing to try {product_focus} for 3-5 appropriate patients over the next month?",
          "secondary_ask": "Can I provide samples and patient education materials today?",
          "tertiary_ask": "May I follow up with you in 4-6 weeks to discuss your experience?"
        },
        "next_steps": [
          "Provide product samples (sufficient for 5-10 patients)",
          "Leave patient education materials",
          "Send clinical reprints and prescribing information",
          "Schedule 4-6 week follow-up",
          "Add to priority call list",
          "Monitor new TRx data"
        ],
        "required_disclaimers": [
          "prescribing_info",
          "individual_results",
          "contraindications",
          "adverse_events"
        ]
      },
      "success_metrics": {
        "primary": "Generate 3+ new TRx within 60 days",
        "secondary": "Increase IBSA share to 20%+ within 90 days",
        "tertiary": "Establish regular call schedule (every 6-8 weeks)"
      }
    },
    "optimization": {
      "scenario": "optimization",
      "target_segment": "Sample Black Holes (receiving samples but low ROI < 5%)",
      "identified_percentage": "48.5%",
      "goal": "Improve sample-to-TRx conversion from <5% to >20%",
      "priority": "MEDIUM",
      "dynamic_slots": [
        "{hcp_name}",
        "{specialty}",
        "{samples_provided}",
        "{trx_generated}",
        "{current_roi}",
        "{target_roi}",
        "{product_focus}"
      ],
      "script_structure": {
        "opening": {
          "greeting": "Good {time_of_day}, Dr. {hcp_name}. Thank you for seeing me today.",
          "purpose": "I wanted to discuss our sampling strategy and make sure we're providing you with resources that truly benefit your patients. I've reviewed our records and want to ensure we're aligned on the best use of samples.",
          "tone": "Collaborative, efficiency-focused, value-optimization"
        },
        "key_talking_points": [
          {
            "point_id": 1,
            "topic": "Sample Usage Review",
            "message": "Over the past quarter, we've provided approximately {samples_provided} samples of {product_focus}. I want to make sure these are reaching the right patients and being used effectively. How have samples been working in your practice?",
            "approved_content_refs": []
          },
          {
            "point_id": 2,
            "topic": "Ideal Patient Profile",
            "message": "To maximize benefit for your patients, {product_focus} is most appropriate for patients with [SPECIFIC CHARACTERISTICS FROM APPROVED CONTENT]. Are these the types of patients receiving samples?",
            "approved_content_refs": [
              "TIR-MSG-001",
              "TIR-CLI-002",
              "FLE-MSG-001"
            ]
          },
          {
            "point_id": 3,
            "topic": "Conversion Strategy",
            "message": "When patients respond well to samples, transitioning to a paid prescription ensures continuity of therapy. What's your typical process for converting patients from samples to prescriptions?",
            "approved_content_refs": []
          },
          {
            "point_id": 4,
            "topic": "Optimized Sample Allocation",
            "message": "Rather than providing large quantities upfront, let's try a more strategic approach: samples for specific patients who are likely to benefit and continue therapy. This ensures better outcomes for your patients and more efficient use of resources.",
            "approved_content_refs": []
          }
        ],
        "objection_handlers": {
          "patients_cant_afford": {
            "objection": "My patients can't afford the medication after samples run out",
            "response": "I understand cost is a significant concern. Let me share information about patient assistance programs and co-pay cards that may help. Also, let's focus samples on patients more likely to have coverage, so they can continue therapy.",
            "approved_content_refs": []
          },
          "samples_for_trial_only": {
            "objection": "I use samples just for short-term trials",
            "response": "That's a valid use case. For trial purposes, could we identify patients most likely to respond and continue therapy? This helps us provide samples where they'll have the greatest impact.",
            "approved_content_refs": []
          },
          "prefer_other_products": {
            "objection": "I prefer other products for long-term therapy",
            "response": "I respect that. Perhaps we can identify the specific patient population where {product_focus} would be your preferred option, and focus our sampling there. That way, samples are used for patients you'd actually prescribe it to.",
            "approved_content_refs": [
              "GEN-OBJ-001"
            ]
          }
        },
        "call_to_action": {
          "primary_ask": "Can we agree on a target of converting at least {target_roi}% of sampled patients to paid prescriptions?",
          "secondary_ask": "Would you be willing to try a more focused sampling approach - smaller quantities for specifically identified patients?",
          "tertiary_ask": "May I check in with you in 6-8 weeks to see how the revised strategy is working?"
        },
        "next_steps": [
          "Reduce sample drop quantity by 30-50%",
          "Provide patient assistance program information",
          "Share ideal patient profile criteria",
          "Schedule 6-8 week follow-up",
          "Monitor sample-to-TRx conversion rate",
          "Redirect excess samples to high-ROI prescribers"
        ],
        "required_disclaimers": [
          "prescribing_info",
          "individual_results"
        ]
      },
      "success_metrics": {
        "primary": "Improve sample-to-TRx conversion to >20%",
        "secondary": "Reduce wasted samples by 40%",
        "tertiary": "Maintain or increase total TRx despite fewer samples"
      }
    },
    "introduction": {
      "scenario": "introduction",
      "target_segment": "New HCPs or first-time territory calls",
      "goal": "Establish professional relationship and introduce IBSA products",
      "priority": "MEDIUM",
      "dynamic_slots": [
        "{hcp_name}",
        "{specialty}",
        "{practice_name}",
        "{years_in_practice}",
        "{patient_volume}",
        "{territory_name}"
      ],
      "script_structure": {
        "opening": {
          "greeting": "Good {time_of_day}, Dr. {hcp_name}. My name is {rep_name}, and I'm the IBSA Pharma territory representative for {territory_name}.",
          "purpose": "Thank you for taking the time to meet with me today. This is my first opportunity to introduce myself and learn more about your practice. I'd like to understand your patient population and discuss how IBSA products might support your treatment goals.",
          "tone": "Professional, respectful, relationship-building"
        },
        "key_talking_points": [
          {
            "point_id": 1,
            "topic": "Professional Introduction",
            "message": "I cover {territory_name} for IBSA Pharma. IBSA focuses on specialty pharmaceutical products, including Tirosint for thyroid disorders, Flector Patch for acute pain, and Licart for angina prevention. Given your {specialty} practice, [ONE OR MORE] may be relevant for your patients.",
            "approved_content_refs": []
          },
          {
            "point_id": 2,
            "topic": "Needs Assessment",
            "message": "To make sure our discussions are valuable for you, could you share a bit about your practice? What are your most common conditions or patient populations? What challenges do you face with current therapies?",
            "approved_content_refs": []
          },
          {
            "point_id": 3,
            "topic": "Product Portfolio Overview",
            "message": "Based on your {specialty} practice, let me highlight [RELEVANT PRODUCT]: [INSERT APPROVED PRODUCT MESSAGING]. Would this be of interest for your patient population?",
            "approved_content_refs": [
              "TIR-MSG-001",
              "FLE-MSG-001",
              "LIC-MSG-001"
            ]
          },
          {
            "point_id": 4,
            "topic": "Value Proposition",
            "message": "My goal is to be a resource for you - whether that's providing clinical information, samples for appropriate patients, or connecting you with our medical science liaisons for detailed questions. How can I best support your practice?",
            "approved_content_refs": []
          }
        ],
        "objection_handlers": {
          "too_busy": {
            "objection": "I'm very busy and don't have time for rep calls",
            "response": "I completely understand - your time is valuable. I'll be brief today and respect your schedule. Perhaps we could establish a regular cadence that works for you - maybe 15 minutes once a quarter? I can also communicate via email if that's more convenient.",
            "approved_content_refs": []
          },
          "dont_see_reps": {
            "objection": "I have a policy of not seeing pharmaceutical representatives",
            "response": "I respect your policy. Would you be open to receiving educational materials and product information by email? I can also arrange for you to speak with our medical science liaison if you have clinical questions that would benefit from a deeper scientific discussion.",
            "approved_content_refs": []
          },
          "satisfied_with_current_options": {
            "objection": "I'm satisfied with my current treatment approach",
            "response": "That's excellent to hear. I'm not here to change what's working well. My goal is simply to make you aware of our products as additional options for those situations where your current approach may not be optimal. May I leave information for your reference?",
            "approved_content_refs": [
              "GEN-OBJ-001"
            ]
          }
        },
        "call_to_action": {
          "primary_ask": "Would you be open to learning more about [MOST RELEVANT PRODUCT] at our next meeting?",
          "secondary_ask": "May I leave product information and samples for your review?",
          "tertiary_ask": "What would be the best way to schedule future visits with you?"
        },
        "next_steps": [
          "Leave business card and contact information",
          "Provide product portfolio overview brochure",
          "Offer samples of most relevant product",
          "Determine preferred contact method and frequency",
          "Add to territory call routing",
          "Send follow-up email with resources"
        ],
        "required_disclaimers": [
          "prescribing_info",
          "indication"
        ]
      },
      "success_metrics": {
        "primary": "Establish regular call schedule",
        "secondary": "Identify 1-2 products of potential interest",
        "tertiary": "Generate first TRx within 90 days"
      }
    }
  }
}